Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic
- 1 January 1994
- journal article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 151 (1) , 133-135
- https://doi.org/10.1176/ajp.151.1.133
Abstract
The authors examined continued neuroleptic exposure following inpatient treatment of mania with neuroleptics and lithium through structured chart review of 40 consecutive patients. At discharge, patients were receiving a mean of 793 mg/day (SD = 695) chlorpromazine equivalents; 6 months later they were receiving a mean of 634 mg/day (SD = 684). This decrease was statistically significant, but the patients' ongoing neuroleptic exposure remained substantial.Keywords
This publication has 7 references indexed in Scilit:
- Prevalence of neuroleptic-induced dystonia in mania and schizophreniaAmerican Journal of Psychiatry, 1990
- Higher frequency of neuroleptic-induced dystonia in mania than in schizophreniaAmerican Journal of Psychiatry, 1988
- Safety of the combination of lithium and neuroleptic drugsAmerican Journal of Psychiatry, 1986
- Comparison of Efficacy of Lithium Carbonate and Chlorpromazine in ManiaArchives of General Psychiatry, 1975
- Comparison of Lithium Carbonate and Chlorpromazine in the Treatment of ManiaArchives of General Psychiatry, 1972
- Lithium-Carbonate Treatment in Depression and ManiaArchives of General Psychiatry, 1969
- THE TREATMENT OF MANIC PSYCHOSES BY THE ADMINISTRATION OF LITHIUM SALTSJournal of Neurology, Neurosurgery & Psychiatry, 1954